Clinical data
AHFS/ Monograph
  • US: D (Evidence of risk)
    Routes of
    intramuscular, intravenous
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data

    84% to 88% IM (est.)[1]

    0% by mouth
    Elimination half-life 5 to 6 hours
    Excretion kidney
    CAS Number
    PubChem CID
    NIAID ChemDB
    PDB ligand
    ECHA InfoCard 100.000.323
    Chemical and physical data
    Formula C21H39N7O12
    Molar mass 581.574 g/mol
    3D model (JSmol)
    Melting point 12 °C (54 °F)
     NY (what is this?)  (verify)

    Streptomycin is an antibiotic used to treat a number of bacterial infections.[2] This includes tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever.[2] For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide.[3] It is given by injection into a vein or muscle.[2]

    Common side effects include vertigo (feeling like the world is spinning), vomiting, numbness of the face, fever, and rash.[2] Use during pregnancy may result in permanent deafness in the baby.[2] Use appears to be safe while breastfeeding.[3] It is not recommended in people with myasthenia gravis.[3] Streptomycin is in the aminoglycoside class of medication.[2] It works by blocking the ability of 30S ribosomal subunits to make proteins which results in bacterial death.[2]

    Streptomycin was discovered in 1943 from Streptomyces griseus.[4][5] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[6] The wholesale cost in the developing world is between 0.38 and 4.39 USD per day.[7] In the United States a course of treatment costs more than 200 USD.[8]



    Streptomycin is traditionally given intramuscularly, and in many nations is only licensed to be administered intramuscularly, though in some regions the drug may also be administered intravenously.[1]


    Streptomycin also is used as a pesticide, to combat the growth of bacteria beyond human applications. Streptomycin controls bacterial diseases of certain fruit, vegetables, seed, and ornamental crops. A major use is in the control of fireblight on apple and pear trees. As in medical applications, extensive use can be associated with the development of resistant strains. Streptomycin could potentially be used to control cyanobacterial blooms in ornamental ponds and aquaria.[9] While some antibacterial antibiotics are inhibitory to certain eukaryotes, this seems not to be the case for streptomycin, especially in the case of anti-fungal activity.[10]

    Cell culture

    Streptomycin, in combination with penicillin, is used in a standard antibiotic cocktail to prevent bacterial infection in cell culture.

    Protein purification

    When purifying protein from a biological extract, streptomycin sulfate is sometimes added as a means of removing nucleic acids. Since it binds to ribosomes and precipitates out of solution, it serves as a method for removing rRNA, mRNA, and even DNA if the extract is from a prokaryote.

    Spectrum of activity

    Streptomycin can be used clinically to treat tuberculosis in combination with other medications and susceptible strains which cause bacterial endocarditis.

    Side effects

    The most concerning side effects, as with other aminoglycosides, are kidney toxicity and ototoxicity.[11] Transient or permanent deafness may result. The vestibular portion of cranial nerve VIII (the vestibulococlear nerve) can be affected, resulting in tinnitus, vertigo, ataxia, kidney toxicity, and can potentially interfere with diagnosis of kidney malfunction.[12]

    Common side effects include feeling like the world is spinning, vomiting, numbness of the face, fever, and rash. Fever and rashes may result from persistent use.

    Use is not recommended during pregnancy.[2] Use appears to be okay while breastfeeding.[3]

    It is not recommended in people with myasthenia gravis.[3]

    Mechanism of action

    Streptomycin is a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit.[13] This leads to codon misreading, eventual inhibition of protein synthesis and ultimately death of microbial cells through mechanisms that are still not understood. Speculation on this mechanism indicates that the binding of the molecule to the 30S subunit interferes with 50S subunit association with the mRNA strand. This results in an unstable ribosomal-mRNA complex, leading to a frameshift mutation and defective protein synthesis; leading to cell death.[14] Humans have ribosomes which are structurally different from those in bacteria, so the drug does not have this effect in human cells. At low concentrations, however, streptomycin only inhibits growth of the bacteria by inducing prokaryotic ribosomes to misread mRNA.[15] Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria,[16] and is therefore a useful broad-spectrum antibiotic.


    Streptomycin was first isolated on October 19, 1943, by Albert Schatz, a PhD student in the laboratory of Selman Abraham Waksman at Rutgers University in a research project funded by Merck and Co.[17][18] Waksman and his laboratory staff discovered several antibiotics, including actinomycin, clavacin, streptothricin, streptomycin, grisein, neomycin, fradicin, candicidin, and candidin. Of these, streptomycin and neomycin found extensive application in the treatment of numerous infectious diseases. Streptomycin was the first antibiotic cure for tuberculosis (TB). In 1952 Waksman was the recipient of the Nobel Prize in Physiology or Medicine in recognition "for his discovery of streptomycin, the first antibiotic active against tuberculosis".[19] Waksman was later accused of playing down the role of Schatz who did the work under his supervision.[20][21][22][23]

    At the end of World War II, the United States Army experimented with streptomycin to treat life-threatening infections at a military hospital in Battle Creek, Michigan. The first patient treated did not survive; the second patient survived but became blind as a side effect of the treatment. In March 1946, the third patientRobert J. Dole, later Majority Leader of the United States Senate and Presidential nomineeexperienced a rapid and robust recovery.[24]

    The first randomized trial of streptomycin against pulmonary tuberculosis was carried out in 1946 through 1948 by the MRC Tuberculosis Research Unit under the chairmanship of Geoffrey Marshall (1887–1982). The trial was neither double-blind nor placebo-controlled.[25] It is widely accepted to have been the first randomised curative trial.[26]

    Results showed efficacy against TB, albeit with minor toxicity and acquired bacterial resistance to the drug.[27]

    New Jersey

    Because streptomycin was isolated from a microbe discovered on New Jersey soil, and because of its activity against tuberculosis and Gram negative organisms, and in recognition of both the microbe and the antibiotic in the history of New Jersey, S. griseus was nominated as the Official New Jersey state microbe. The draft legislation was submitted by Senator Sam Thompson (R-12) in May 2017 as bill S3190 and Assemblywoman Annette Quijano (D-20) in June 2017 as bill A31900.[28][29]

    See also

    • Philip D'Arcy Hart - The British medical researcher and pioneer in tuberculosis treatment in the early twentieth century.


    1. 1 2 Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA (October 2001). "Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis". Pharmacotherapy. 21 (9): 1037–1045. doi:10.1592/phco.21.13.1037.34625. PMID 11560193. Archived from the original on 2011-10-05. Retrieved 2010-05-25.
    2. 1 2 3 4 5 6 7 8 "Streptomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
    3. 1 2 3 4 5 6 WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 136, 144, 609. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
    4. Torok, Estee; Moran, Ed; Cooke, Fiona (2009). Oxford Handbook of Infectious Diseases and Microbiology. OUP Oxford. p. Chapter 2. ISBN 9780191039621. Archived from the original on 2017-09-08.
    5. Renneberg, Reinhard; Demain, Arnold L. (2008). Biotechnology for Beginners. Elsevier. p. 103. ISBN 9780123735812. Archived from the original on 2017-09-10.
    6. "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
    7. "Streptomycin Sulfate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
    8. Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 36. ISBN 9781284057560.
    9. Qian, H., Li, J., Pan, X., Sun, Z., Ye, C., Jin, G., & Fu, Z. (2012). "Effects of streptomycin on growth of algae Chlorella vulgaris and Microcystis aeruginosa". Environmental Toxicology. 27 (4): 229–237.
    10. Reilly, H. C., Schatz, A., & Waksman, S. A. (1945). "Antifungal properties of antibiotic substances". Journal of Bacteriology. 49 (6): 585–594. PMC 374091. PMID 16560957.
    11. "Archived copy". Archived from the original on 2017-01-06. Retrieved 2017-01-05.
    12. Syal K, Srinivasan A, Banerjee D (2013). "Streptomycin interference in Jaffe reaction — Possible false positive creatinine estimation in excessive dose exposure". Clinical Biochemistry. 46: 177–179. doi:10.1016/j.clinbiochem.2012.10.031.
    13. Sharma D, Cukras AR, Rogers EJ, Southworth DR, Green R (7 December 2007). "Mutational analysis of S12 protein and implications for the accuracy of decoding by the ribosome". Journal of Molecular Biology. 374 (4): 1065–76. doi:10.1016/j.jmb.2007.10.003. PMC 2200631. PMID 17967466.
    14. Raymon, Lionel P. (2011). COMLEX Level 1 Pharmacology Lecture Notes. Miami, FL: Kaplan, Inc. p. 181. CM4024K.
    15. Voet, Donald & Voet, Judith G. (2004). Biochemistry (3rd ed.). John Wiley & Sons. p. 1341. ISBN 0-471-19350-X.
    16. Jan-Thorsten Schantz; Kee-Woei Ng (2004). A manual for primary human cell culture. World Scientific. p. 89.
    17. Comroe JH Jr (1978). "Pay dirt: the story of streptomycin. Part I: from Waksman to Waksman". American Review of Respiratory Disease. 117 (4): 773–781. doi:10.1164/arrd.1978.117.4.773. PMID 417651.
    18. Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". J Hist Med Allied Sci. 59 (3): 441–62. doi:10.1093/jhmas/jrh091. PMID 15270337.
    19. Official list of Nobel Prize Laureates in Medicine Archived 2017-06-09 at the Wayback Machine.
    20. Wainwright, M. (1990). Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics. Blackwell. ISBN 9780631164920. Archived from the original on 2017-09-10. Retrieved 2014-12-29.
    21. Wainwright, M. (1991). "Streptomycin: discovery and resultant controversy". Journal of the History and Philosophy of the Life Sciences. 13: 97–124.
    22. Kingston, William (2004-07-01). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". Journal of the History of Medicine and Allied Sciences. 59 (3): 441–462. doi:10.1093/jhmas/jrh091. ISSN 0022-5045. PMID 15270337.
    23. Pringle, Peter (2012). Experiment Eleven: Dark Secrets Behind the Discovery of a Wonder Drug. New York: Walker & Company. ISBN 978-1620401989.
    24. Cramer, Richard Ben, What It Takes (New York, 1992), pp. 110-11.
    25. Hart, P. D. A. (1999) A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s. BMJ: British Medical Journal, 319(7209), 572.
    26. Metcalfe NH (February 2011). "Sir Geoffrey Marshall (1887-1982): respiratory physician, catalyst for anaesthesia development, doctor to both Prime Minister and King, and World War I Barge Commander". J Med Biogr. 19 (1): 10–4. doi:10.1258/jmb.2010.010019. PMID 21350072.
    27. D'Arcy Hart P (August 1999). "A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s". British Medical Journal. 319 (7209): 572–3. doi:10.1136/bmj.319.7209.572. PMC 1116443. PMID 10463905.
    28. "New Jersey S3190 | 2016-2017 | Regular Session". LegiScan. Retrieved 2017-11-29.
    29. "New Jersey A4900 | 2016-2017 | Regular Session". LegiScan. Retrieved 2017-11-29.

    Further reading

    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.